Global Neuromodulation

Neuromodulation Comprehensive Study by Application (Depression, Parkinson's, Tinnitus, Alzheimer's, Epilepsy, Ischemia, Obesity), Technology (Internal Neuromodulation, External Neuromodulation), End Use (Spinal Cord Stimulation, Deep Brain Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, Respiratory Electrical Stimulation, Other) Players and Region - Global Market Outlook to 2026

Neuromodulation Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Neuromodulation Market Overview:
Neurological disorders such as epilepsy, Alzheimer disease, cerebrovascular diseases, and Parkinson's disease affect the central and peripheral nervous system. Bacterial, viral, and fungal infections can also cause neurological disorders. To manage such disorders, neuromodulation is used, wherein small electrodes generate electrical most precise stimulation with the help of pulse generators to supplement neurological activities in effected people. The electrodes are generally placed directly in the brain or peripheral nerves or spinal cord whereas pulse generators are implanted within the skin. Some of the players profiled in the study are Medtronic (Ireland), Boston Scientific Corporation (United States), Abbott (United States), LivaNova (United Kingdom), Synapse Biomedical (United States), Nevro Corporation (United States), NeuroSigma (United States), NeuroPace (United States), Neuronetics (United States) and BioControl Medical (Israel).

On the basis of geography, the market of Neuromodulation has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Technology, the sub-segment i.e. Internal Neuromodulation will boost the Neuromodulation market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End Use, the sub-segment i.e. Spinal Cord Stimulation will boost the Neuromodulation market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Rising Prevalence of Neurological Disorders
  • Rising Awareness on Neurodegenerative Disorders

Influencing Trend
  • Research Into Expanding the Applications of Neuromodulation

Restraints
  • High Cost of Neuromodulation Procedures

Opportunities
  • Expansion in Emerging Economies

Challenges
  • Dearth of Trained Professionals




The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Target Audience:
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Hospital and Medical Sectors, Government Regulatory and Research Organizations and End-Use Industries

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Neuromodulation market on the basis of product [] , application [Depression, Parkinson's, Tinnitus, Alzheimer's, Epilepsy, Ischemia and Obesity], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Neuromodulation market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Neuromodulation industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Bioness (United States), Soterix Medical (United States), Integer Holdings Corporation (United States) and Bioinduction (United Kingdom).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Neuromodulation market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Application
  • Depression
  • Parkinson's
  • Tinnitus
  • Alzheimer's
  • Epilepsy
  • Ischemia
  • Obesity
By Technology
  • Internal Neuromodulation
  • External Neuromodulation

By End Use
  • Spinal Cord Stimulation
  • Deep Brain Stimulation
  • Sacral Nerve Stimulation
  • Vagus Nerve Stimulation
  • Respiratory Electrical Stimulation
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Neurological Disorders
      • 3.2.2. Rising Awareness on Neurodegenerative Disorders
    • 3.3. Market Challenges
      • 3.3.1. Dearth of Trained Professionals
    • 3.4. Market Trends
      • 3.4.1. Research Into Expanding the Applications of Neuromodulation
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neuromodulation, by Application, Technology, End Use and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Neuromodulation (Value)
      • 5.2.1. Global Neuromodulation by: Application (Value)
        • 5.2.1.1. Depression
        • 5.2.1.2. Parkinson's
        • 5.2.1.3. Tinnitus
        • 5.2.1.4. Alzheimer's
        • 5.2.1.5. Epilepsy
        • 5.2.1.6. Ischemia
        • 5.2.1.7. Obesity
      • 5.2.2. Global Neuromodulation by: Technology (Value)
        • 5.2.2.1. Internal Neuromodulation
        • 5.2.2.2. External Neuromodulation
      • 5.2.3. Global Neuromodulation by: End Use (Value)
        • 5.2.3.1. Spinal Cord Stimulation
        • 5.2.3.2. Deep Brain Stimulation
        • 5.2.3.3. Sacral Nerve Stimulation
        • 5.2.3.4. Vagus Nerve Stimulation
        • 5.2.3.5. Respiratory Electrical Stimulation
        • 5.2.3.6. Other
      • 5.2.4. Global Neuromodulation Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Neuromodulation: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Medtronic (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Boston Scientific Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abbott (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. LivaNova (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Synapse Biomedical (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Nevro Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. NeuroSigma (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. NeuroPace (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Neuronetics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. BioControl Medical (Israel)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Neuromodulation Sale, by Application, Technology, End Use and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Neuromodulation (Value)
      • 7.2.1. Global Neuromodulation by: Application (Value)
        • 7.2.1.1. Depression
        • 7.2.1.2. Parkinson's
        • 7.2.1.3. Tinnitus
        • 7.2.1.4. Alzheimer's
        • 7.2.1.5. Epilepsy
        • 7.2.1.6. Ischemia
        • 7.2.1.7. Obesity
      • 7.2.2. Global Neuromodulation by: Technology (Value)
        • 7.2.2.1. Internal Neuromodulation
        • 7.2.2.2. External Neuromodulation
      • 7.2.3. Global Neuromodulation by: End Use (Value)
        • 7.2.3.1. Spinal Cord Stimulation
        • 7.2.3.2. Deep Brain Stimulation
        • 7.2.3.3. Sacral Nerve Stimulation
        • 7.2.3.4. Vagus Nerve Stimulation
        • 7.2.3.5. Respiratory Electrical Stimulation
        • 7.2.3.6. Other
      • 7.2.4. Global Neuromodulation Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neuromodulation: by Application(USD Million)
  • Table 2. Neuromodulation Depression , by Region USD Million (2015-2020)
  • Table 3. Neuromodulation Parkinson's , by Region USD Million (2015-2020)
  • Table 4. Neuromodulation Tinnitus , by Region USD Million (2015-2020)
  • Table 5. Neuromodulation Alzheimer's , by Region USD Million (2015-2020)
  • Table 6. Neuromodulation Epilepsy , by Region USD Million (2015-2020)
  • Table 7. Neuromodulation Ischemia , by Region USD Million (2015-2020)
  • Table 8. Neuromodulation Obesity , by Region USD Million (2015-2020)
  • Table 9. Neuromodulation: by Technology(USD Million)
  • Table 10. Neuromodulation Internal Neuromodulation , by Region USD Million (2015-2020)
  • Table 11. Neuromodulation External Neuromodulation , by Region USD Million (2015-2020)
  • Table 12. Neuromodulation: by End Use(USD Million)
  • Table 13. Neuromodulation Spinal Cord Stimulation , by Region USD Million (2015-2020)
  • Table 14. Neuromodulation Deep Brain Stimulation , by Region USD Million (2015-2020)
  • Table 15. Neuromodulation Sacral Nerve Stimulation , by Region USD Million (2015-2020)
  • Table 16. Neuromodulation Vagus Nerve Stimulation , by Region USD Million (2015-2020)
  • Table 17. Neuromodulation Respiratory Electrical Stimulation , by Region USD Million (2015-2020)
  • Table 18. Neuromodulation Other , by Region USD Million (2015-2020)
  • Table 19. South America Neuromodulation, by Country USD Million (2015-2020)
  • Table 20. South America Neuromodulation, by Application USD Million (2015-2020)
  • Table 21. South America Neuromodulation, by Technology USD Million (2015-2020)
  • Table 22. South America Neuromodulation, by End Use USD Million (2015-2020)
  • Table 23. Brazil Neuromodulation, by Application USD Million (2015-2020)
  • Table 24. Brazil Neuromodulation, by Technology USD Million (2015-2020)
  • Table 25. Brazil Neuromodulation, by End Use USD Million (2015-2020)
  • Table 26. Argentina Neuromodulation, by Application USD Million (2015-2020)
  • Table 27. Argentina Neuromodulation, by Technology USD Million (2015-2020)
  • Table 28. Argentina Neuromodulation, by End Use USD Million (2015-2020)
  • Table 29. Rest of South America Neuromodulation, by Application USD Million (2015-2020)
  • Table 30. Rest of South America Neuromodulation, by Technology USD Million (2015-2020)
  • Table 31. Rest of South America Neuromodulation, by End Use USD Million (2015-2020)
  • Table 32. Asia Pacific Neuromodulation, by Country USD Million (2015-2020)
  • Table 33. Asia Pacific Neuromodulation, by Application USD Million (2015-2020)
  • Table 34. Asia Pacific Neuromodulation, by Technology USD Million (2015-2020)
  • Table 35. Asia Pacific Neuromodulation, by End Use USD Million (2015-2020)
  • Table 36. China Neuromodulation, by Application USD Million (2015-2020)
  • Table 37. China Neuromodulation, by Technology USD Million (2015-2020)
  • Table 38. China Neuromodulation, by End Use USD Million (2015-2020)
  • Table 39. Japan Neuromodulation, by Application USD Million (2015-2020)
  • Table 40. Japan Neuromodulation, by Technology USD Million (2015-2020)
  • Table 41. Japan Neuromodulation, by End Use USD Million (2015-2020)
  • Table 42. India Neuromodulation, by Application USD Million (2015-2020)
  • Table 43. India Neuromodulation, by Technology USD Million (2015-2020)
  • Table 44. India Neuromodulation, by End Use USD Million (2015-2020)
  • Table 45. South Korea Neuromodulation, by Application USD Million (2015-2020)
  • Table 46. South Korea Neuromodulation, by Technology USD Million (2015-2020)
  • Table 47. South Korea Neuromodulation, by End Use USD Million (2015-2020)
  • Table 48. Taiwan Neuromodulation, by Application USD Million (2015-2020)
  • Table 49. Taiwan Neuromodulation, by Technology USD Million (2015-2020)
  • Table 50. Taiwan Neuromodulation, by End Use USD Million (2015-2020)
  • Table 51. Australia Neuromodulation, by Application USD Million (2015-2020)
  • Table 52. Australia Neuromodulation, by Technology USD Million (2015-2020)
  • Table 53. Australia Neuromodulation, by End Use USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Neuromodulation, by Application USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Neuromodulation, by Technology USD Million (2015-2020)
  • Table 56. Rest of Asia-Pacific Neuromodulation, by End Use USD Million (2015-2020)
  • Table 57. Europe Neuromodulation, by Country USD Million (2015-2020)
  • Table 58. Europe Neuromodulation, by Application USD Million (2015-2020)
  • Table 59. Europe Neuromodulation, by Technology USD Million (2015-2020)
  • Table 60. Europe Neuromodulation, by End Use USD Million (2015-2020)
  • Table 61. Germany Neuromodulation, by Application USD Million (2015-2020)
  • Table 62. Germany Neuromodulation, by Technology USD Million (2015-2020)
  • Table 63. Germany Neuromodulation, by End Use USD Million (2015-2020)
  • Table 64. France Neuromodulation, by Application USD Million (2015-2020)
  • Table 65. France Neuromodulation, by Technology USD Million (2015-2020)
  • Table 66. France Neuromodulation, by End Use USD Million (2015-2020)
  • Table 67. Italy Neuromodulation, by Application USD Million (2015-2020)
  • Table 68. Italy Neuromodulation, by Technology USD Million (2015-2020)
  • Table 69. Italy Neuromodulation, by End Use USD Million (2015-2020)
  • Table 70. United Kingdom Neuromodulation, by Application USD Million (2015-2020)
  • Table 71. United Kingdom Neuromodulation, by Technology USD Million (2015-2020)
  • Table 72. United Kingdom Neuromodulation, by End Use USD Million (2015-2020)
  • Table 73. Netherlands Neuromodulation, by Application USD Million (2015-2020)
  • Table 74. Netherlands Neuromodulation, by Technology USD Million (2015-2020)
  • Table 75. Netherlands Neuromodulation, by End Use USD Million (2015-2020)
  • Table 76. Rest of Europe Neuromodulation, by Application USD Million (2015-2020)
  • Table 77. Rest of Europe Neuromodulation, by Technology USD Million (2015-2020)
  • Table 78. Rest of Europe Neuromodulation, by End Use USD Million (2015-2020)
  • Table 79. MEA Neuromodulation, by Country USD Million (2015-2020)
  • Table 80. MEA Neuromodulation, by Application USD Million (2015-2020)
  • Table 81. MEA Neuromodulation, by Technology USD Million (2015-2020)
  • Table 82. MEA Neuromodulation, by End Use USD Million (2015-2020)
  • Table 83. Middle East Neuromodulation, by Application USD Million (2015-2020)
  • Table 84. Middle East Neuromodulation, by Technology USD Million (2015-2020)
  • Table 85. Middle East Neuromodulation, by End Use USD Million (2015-2020)
  • Table 86. Africa Neuromodulation, by Application USD Million (2015-2020)
  • Table 87. Africa Neuromodulation, by Technology USD Million (2015-2020)
  • Table 88. Africa Neuromodulation, by End Use USD Million (2015-2020)
  • Table 89. North America Neuromodulation, by Country USD Million (2015-2020)
  • Table 90. North America Neuromodulation, by Application USD Million (2015-2020)
  • Table 91. North America Neuromodulation, by Technology USD Million (2015-2020)
  • Table 92. North America Neuromodulation, by End Use USD Million (2015-2020)
  • Table 93. United States Neuromodulation, by Application USD Million (2015-2020)
  • Table 94. United States Neuromodulation, by Technology USD Million (2015-2020)
  • Table 95. United States Neuromodulation, by End Use USD Million (2015-2020)
  • Table 96. Canada Neuromodulation, by Application USD Million (2015-2020)
  • Table 97. Canada Neuromodulation, by Technology USD Million (2015-2020)
  • Table 98. Canada Neuromodulation, by End Use USD Million (2015-2020)
  • Table 99. Mexico Neuromodulation, by Application USD Million (2015-2020)
  • Table 100. Mexico Neuromodulation, by Technology USD Million (2015-2020)
  • Table 101. Mexico Neuromodulation, by End Use USD Million (2015-2020)
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Neuromodulation: by Application(USD Million)
  • Table 113. Neuromodulation Depression , by Region USD Million (2021-2026)
  • Table 114. Neuromodulation Parkinson's , by Region USD Million (2021-2026)
  • Table 115. Neuromodulation Tinnitus , by Region USD Million (2021-2026)
  • Table 116. Neuromodulation Alzheimer's , by Region USD Million (2021-2026)
  • Table 117. Neuromodulation Epilepsy , by Region USD Million (2021-2026)
  • Table 118. Neuromodulation Ischemia , by Region USD Million (2021-2026)
  • Table 119. Neuromodulation Obesity , by Region USD Million (2021-2026)
  • Table 120. Neuromodulation: by Technology(USD Million)
  • Table 121. Neuromodulation Internal Neuromodulation , by Region USD Million (2021-2026)
  • Table 122. Neuromodulation External Neuromodulation , by Region USD Million (2021-2026)
  • Table 123. Neuromodulation: by End Use(USD Million)
  • Table 124. Neuromodulation Spinal Cord Stimulation , by Region USD Million (2021-2026)
  • Table 125. Neuromodulation Deep Brain Stimulation , by Region USD Million (2021-2026)
  • Table 126. Neuromodulation Sacral Nerve Stimulation , by Region USD Million (2021-2026)
  • Table 127. Neuromodulation Vagus Nerve Stimulation , by Region USD Million (2021-2026)
  • Table 128. Neuromodulation Respiratory Electrical Stimulation , by Region USD Million (2021-2026)
  • Table 129. Neuromodulation Other , by Region USD Million (2021-2026)
  • Table 130. South America Neuromodulation, by Country USD Million (2021-2026)
  • Table 131. South America Neuromodulation, by Application USD Million (2021-2026)
  • Table 132. South America Neuromodulation, by Technology USD Million (2021-2026)
  • Table 133. South America Neuromodulation, by End Use USD Million (2021-2026)
  • Table 134. Brazil Neuromodulation, by Application USD Million (2021-2026)
  • Table 135. Brazil Neuromodulation, by Technology USD Million (2021-2026)
  • Table 136. Brazil Neuromodulation, by End Use USD Million (2021-2026)
  • Table 137. Argentina Neuromodulation, by Application USD Million (2021-2026)
  • Table 138. Argentina Neuromodulation, by Technology USD Million (2021-2026)
  • Table 139. Argentina Neuromodulation, by End Use USD Million (2021-2026)
  • Table 140. Rest of South America Neuromodulation, by Application USD Million (2021-2026)
  • Table 141. Rest of South America Neuromodulation, by Technology USD Million (2021-2026)
  • Table 142. Rest of South America Neuromodulation, by End Use USD Million (2021-2026)
  • Table 143. Asia Pacific Neuromodulation, by Country USD Million (2021-2026)
  • Table 144. Asia Pacific Neuromodulation, by Application USD Million (2021-2026)
  • Table 145. Asia Pacific Neuromodulation, by Technology USD Million (2021-2026)
  • Table 146. Asia Pacific Neuromodulation, by End Use USD Million (2021-2026)
  • Table 147. China Neuromodulation, by Application USD Million (2021-2026)
  • Table 148. China Neuromodulation, by Technology USD Million (2021-2026)
  • Table 149. China Neuromodulation, by End Use USD Million (2021-2026)
  • Table 150. Japan Neuromodulation, by Application USD Million (2021-2026)
  • Table 151. Japan Neuromodulation, by Technology USD Million (2021-2026)
  • Table 152. Japan Neuromodulation, by End Use USD Million (2021-2026)
  • Table 153. India Neuromodulation, by Application USD Million (2021-2026)
  • Table 154. India Neuromodulation, by Technology USD Million (2021-2026)
  • Table 155. India Neuromodulation, by End Use USD Million (2021-2026)
  • Table 156. South Korea Neuromodulation, by Application USD Million (2021-2026)
  • Table 157. South Korea Neuromodulation, by Technology USD Million (2021-2026)
  • Table 158. South Korea Neuromodulation, by End Use USD Million (2021-2026)
  • Table 159. Taiwan Neuromodulation, by Application USD Million (2021-2026)
  • Table 160. Taiwan Neuromodulation, by Technology USD Million (2021-2026)
  • Table 161. Taiwan Neuromodulation, by End Use USD Million (2021-2026)
  • Table 162. Australia Neuromodulation, by Application USD Million (2021-2026)
  • Table 163. Australia Neuromodulation, by Technology USD Million (2021-2026)
  • Table 164. Australia Neuromodulation, by End Use USD Million (2021-2026)
  • Table 165. Rest of Asia-Pacific Neuromodulation, by Application USD Million (2021-2026)
  • Table 166. Rest of Asia-Pacific Neuromodulation, by Technology USD Million (2021-2026)
  • Table 167. Rest of Asia-Pacific Neuromodulation, by End Use USD Million (2021-2026)
  • Table 168. Europe Neuromodulation, by Country USD Million (2021-2026)
  • Table 169. Europe Neuromodulation, by Application USD Million (2021-2026)
  • Table 170. Europe Neuromodulation, by Technology USD Million (2021-2026)
  • Table 171. Europe Neuromodulation, by End Use USD Million (2021-2026)
  • Table 172. Germany Neuromodulation, by Application USD Million (2021-2026)
  • Table 173. Germany Neuromodulation, by Technology USD Million (2021-2026)
  • Table 174. Germany Neuromodulation, by End Use USD Million (2021-2026)
  • Table 175. France Neuromodulation, by Application USD Million (2021-2026)
  • Table 176. France Neuromodulation, by Technology USD Million (2021-2026)
  • Table 177. France Neuromodulation, by End Use USD Million (2021-2026)
  • Table 178. Italy Neuromodulation, by Application USD Million (2021-2026)
  • Table 179. Italy Neuromodulation, by Technology USD Million (2021-2026)
  • Table 180. Italy Neuromodulation, by End Use USD Million (2021-2026)
  • Table 181. United Kingdom Neuromodulation, by Application USD Million (2021-2026)
  • Table 182. United Kingdom Neuromodulation, by Technology USD Million (2021-2026)
  • Table 183. United Kingdom Neuromodulation, by End Use USD Million (2021-2026)
  • Table 184. Netherlands Neuromodulation, by Application USD Million (2021-2026)
  • Table 185. Netherlands Neuromodulation, by Technology USD Million (2021-2026)
  • Table 186. Netherlands Neuromodulation, by End Use USD Million (2021-2026)
  • Table 187. Rest of Europe Neuromodulation, by Application USD Million (2021-2026)
  • Table 188. Rest of Europe Neuromodulation, by Technology USD Million (2021-2026)
  • Table 189. Rest of Europe Neuromodulation, by End Use USD Million (2021-2026)
  • Table 190. MEA Neuromodulation, by Country USD Million (2021-2026)
  • Table 191. MEA Neuromodulation, by Application USD Million (2021-2026)
  • Table 192. MEA Neuromodulation, by Technology USD Million (2021-2026)
  • Table 193. MEA Neuromodulation, by End Use USD Million (2021-2026)
  • Table 194. Middle East Neuromodulation, by Application USD Million (2021-2026)
  • Table 195. Middle East Neuromodulation, by Technology USD Million (2021-2026)
  • Table 196. Middle East Neuromodulation, by End Use USD Million (2021-2026)
  • Table 197. Africa Neuromodulation, by Application USD Million (2021-2026)
  • Table 198. Africa Neuromodulation, by Technology USD Million (2021-2026)
  • Table 199. Africa Neuromodulation, by End Use USD Million (2021-2026)
  • Table 200. North America Neuromodulation, by Country USD Million (2021-2026)
  • Table 201. North America Neuromodulation, by Application USD Million (2021-2026)
  • Table 202. North America Neuromodulation, by Technology USD Million (2021-2026)
  • Table 203. North America Neuromodulation, by End Use USD Million (2021-2026)
  • Table 204. United States Neuromodulation, by Application USD Million (2021-2026)
  • Table 205. United States Neuromodulation, by Technology USD Million (2021-2026)
  • Table 206. United States Neuromodulation, by End Use USD Million (2021-2026)
  • Table 207. Canada Neuromodulation, by Application USD Million (2021-2026)
  • Table 208. Canada Neuromodulation, by Technology USD Million (2021-2026)
  • Table 209. Canada Neuromodulation, by End Use USD Million (2021-2026)
  • Table 210. Mexico Neuromodulation, by Application USD Million (2021-2026)
  • Table 211. Mexico Neuromodulation, by Technology USD Million (2021-2026)
  • Table 212. Mexico Neuromodulation, by End Use USD Million (2021-2026)
  • Table 213. Research Programs/Design for This Report
  • Table 214. Key Data Information from Secondary Sources
  • Table 215. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neuromodulation: by Application USD Million (2015-2020)
  • Figure 5. Global Neuromodulation: by Technology USD Million (2015-2020)
  • Figure 6. Global Neuromodulation: by End Use USD Million (2015-2020)
  • Figure 7. South America Neuromodulation Share (%), by Country
  • Figure 8. Asia Pacific Neuromodulation Share (%), by Country
  • Figure 9. Europe Neuromodulation Share (%), by Country
  • Figure 10. MEA Neuromodulation Share (%), by Country
  • Figure 11. North America Neuromodulation Share (%), by Country
  • Figure 12. Global Neuromodulation share by Players 2020 (%)
  • Figure 13. Global Neuromodulation share by Players (Top 3) 2020(%)
  • Figure 14. Global Neuromodulation share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Medtronic (Ireland) Revenue, Net Income and Gross profit
  • Figure 17. Medtronic (Ireland) Revenue: by Geography 2020
  • Figure 18. Boston Scientific Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 19. Boston Scientific Corporation (United States) Revenue: by Geography 2020
  • Figure 20. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 21. Abbott (United States) Revenue: by Geography 2020
  • Figure 22. LivaNova (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. LivaNova (United Kingdom) Revenue: by Geography 2020
  • Figure 24. Synapse Biomedical (United States) Revenue, Net Income and Gross profit
  • Figure 25. Synapse Biomedical (United States) Revenue: by Geography 2020
  • Figure 26. Nevro Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 27. Nevro Corporation (United States) Revenue: by Geography 2020
  • Figure 28. NeuroSigma (United States) Revenue, Net Income and Gross profit
  • Figure 29. NeuroSigma (United States) Revenue: by Geography 2020
  • Figure 30. NeuroPace (United States) Revenue, Net Income and Gross profit
  • Figure 31. NeuroPace (United States) Revenue: by Geography 2020
  • Figure 32. Neuronetics (United States) Revenue, Net Income and Gross profit
  • Figure 33. Neuronetics (United States) Revenue: by Geography 2020
  • Figure 34. BioControl Medical (Israel) Revenue, Net Income and Gross profit
  • Figure 35. BioControl Medical (Israel) Revenue: by Geography 2020
  • Figure 36. Global Neuromodulation: by Application USD Million (2021-2026)
  • Figure 37. Global Neuromodulation: by Technology USD Million (2021-2026)
  • Figure 38. Global Neuromodulation: by End Use USD Million (2021-2026)
  • Figure 39. South America Neuromodulation Share (%), by Country
  • Figure 40. Asia Pacific Neuromodulation Share (%), by Country
  • Figure 41. Europe Neuromodulation Share (%), by Country
  • Figure 42. MEA Neuromodulation Share (%), by Country
  • Figure 43. North America Neuromodulation Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Medtronic (Ireland)
  • Boston Scientific Corporation (United States)
  • Abbott (United States)
  • LivaNova (United Kingdom)
  • Synapse Biomedical (United States)
  • Nevro Corporation (United States)
  • NeuroSigma (United States)
  • NeuroPace (United States)
  • Neuronetics (United States)
  • BioControl Medical (Israel)
Additional players considered in the study are as follows:
Bioness (United States) , Soterix Medical (United States) , Integer Holdings Corporation (United States) , Bioinduction (United Kingdom)
Select User Access Type

Key Highlights of Report


Feb 2021 235 Pages 84 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Neuromodulation Quantitative research analysis
Global Neuromodulation Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Neuromodulation Report?

Have a Query? Click Here

Other Related Reports

Health Care Mobility Solutions Comprehensive Study by Type (Mobile Devices, Mobile Applications (Apps), Enterprise Mobility Platforms), Application (Enterprise Solutions {Patient Care Management, Ope...
$ 3650
Physician Practice Management Comprehensive Study by Application (Private Practice, Group Practice, Large Health Maintenance Organizations (HMOs), Others), Deployment Type (On-premise, Cloud-based, W...
$ 3750
e-Clinical Trial Technologies Comprehensive Study by Phase (Phase I, Phase II, Phase III, Phase IV), Electronics Solutions (Clinical Analytics Platforms, Electronic Data Capture (EDC), Clinical Data ...
$ 3750
Natural Language Processing (NLP) in Healthcare Comprehensive Study by Type (Rule-Based NLP, Statistically Based NLP, Mixed NLP), Application (Health Care, Life Science, Other), Organization Size (Sm...
$ 3750
Implantable Drug Delivery Systems Comprehensive Study by Type (Contraceptive Implants, Spinal Implants, Brachytherapy Seeds, Drug-Eluting Stents, Bio-absorbable Stents, Intraocular Stents, Infusion P...
$ 3750
Medical Imaging Technology Comprehensive Study by Application (Orthopedics, Cardiology, Urology, Gastrology, Neurology, Others), Imaging Technology (Radiography, Computed Tomography, Magnetic Resonan...
$ 3650